Phase 1 EGFR Mutation Clinical Trials

5 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–5 of 5 trials

Recruiting

Phase 1Phase 2

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation

Bayer400 enrolled94 locationsNCT05099172

Recruiting

Phase 1

Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

EGFR Mutation-positive NSCLC

AstraZeneca12 enrolled3 locationsNCT07500987

Recruiting

Phase 1

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients

Nuvectis Pharma, Inc.18 enrolled3 locationsNCT07315113

Recruiting

Phase 1Phase 2

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989

Recruiting

Phase 1Phase 2

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

Suzhou Genhouse Bio Co., Ltd.94 enrolled6 locationsNCT06306456